{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:22:15Z","timestamp":1773422535942,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,13]]},"DOI":"10.7759\/cureus.105176","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:45:26Z","timestamp":1773420326000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Tolerability of Viloxazine Extended-Release for Attention-Deficit\/Hyperactivity Disorder in Adolescents and Adults: A Systematic Review With Qualitative Synthesis of All Studies and Meta-Analysis of Adolescent Data"],"prefix":"10.7759","author":[{"given":"Savannah R","family":"Chapman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Roberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Abouafech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33004-1","article-title":"Attention-deficit hyperactivity disorder","volume":"395","author":"Posner J","year":"2020","unstructured":"Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet. 2020, 395:450-62. 10.1016\/S0140-6736(19)33004-1","journal-title":"Lancet"},{"key":"ref2","article-title":"Evaluation and treatment of ADHD","volume":"64","author":"Smucker WD","year":"2001","unstructured":"Smucker WD, Hedayat M. Evaluation and treatment of ADHD. Am Fam Physician. 2001, 64:817-29.","journal-title":"Am Fam Physician"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00238-X","article-title":"Attention deficit hyperactivity disorder","volume":"387","author":"Thapar A","year":"2016","unstructured":"Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 2016, 387:1240-50. 10.1016\/S0140-6736(15)00238-X","journal-title":"Lancet"},{"key":"ref4","unstructured":"U.S. National Library of Medicine. Qelbree (viloxazine extended-release) label. DailyMed. (2025). https.\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=3d1f5aff-5d39-496c-b5ed-7f3c70ec641c."},{"key":"ref5","article-title":"Viloxazine","author":"Mathew BM","year":"2025","unstructured":"Mathew BM, Pellegrini MV. Viloxazine. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-025-01227-y","article-title":"Viloxazine extended-release: a review in attention-deficit\/hyperactivity disorder in adults","volume":"39","author":"Syed YY","year":"2025","unstructured":"Syed YY. Viloxazine extended-release: a review in attention-deficit\/hyperactivity disorder in adults. CNS Drugs. 2025, 39:1355-64. 10.1007\/s40263-025-01227-y","journal-title":"CNS Drugs"},{"key":"ref7","unstructured":"MedlinePlus Genetics. Attention-deficit\/hyperactivity disorder. U.S. National Library of Medicine. (ND). Accessed. January 23, 2026: https:\/\/medlineplus.gov\/genetics\/condition\/attention-deficit-hyperactivity-disorder\/."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.883578","article-title":"Psychometric properties of ADHD rating scale-5 for children and adolescents in Sudan-school version","volume":"13","author":"Alhossein A","year":"2022","unstructured":"Alhossein A, Abaoud AA, Becker D, et al.. Psychometric properties of ADHD rating scale-5 for children and adolescents in Sudan-school version. Front Psychol. 2022, 13:883578. 10.3389\/fpsyg.2022.883578","journal-title":"Front Psychol"},{"key":"ref9","article-title":"Attention-deficit\/hyperactivity disorder in adults","volume":"110","author":"Olagunju AE","year":"2024","unstructured":"Olagunju AE, Ghoddusi F. Attention-deficit\/hyperactivity disorder in adults. Am Fam Physician. 2024, 110:157-66.","journal-title":"Am Fam Physician"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref11","article-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2022","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Publishing, Washington, DC; 2022. https:\/\/www.psychiatry.org\/psychiatrists\/practice\/dsm."},{"key":"ref12","unstructured":"Study quality assessment tools. (2021). Accessed. January 4, 2026: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"ref13","article-title":"Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3","author":"Higgins JPT","year":"2022","unstructured":"Higgins JPT, Thomas J, Chandler J, et al.. Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3. Cochrane, London, UK; 2022."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00938-w","article-title":"A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit\/hyperactivity disorder","volume":"36","author":"Nasser A","year":"2022","unstructured":"Nasser A, Hull JT, Chaturvedi SA, et al.. A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit\/hyperactivity disorder. CNS Drugs. 2022, 36:897-915. 10.1007\/s40263-022-00938-w","journal-title":"CNS Drugs"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001404","article-title":"A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit\/hyperactivity disorder","volume":"41","author":"Nasser A","year":"2021","unstructured":"Nasser A, Liranso T, Adewole T, et al.. A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit\/hyperactivity disorder. J Clin Psychopharmacol. 2021, 41:370-80. 10.1097\/JCP.0000000000001404","journal-title":"J Clin Psychopharmacol"},{"key":"ref16","article-title":"A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD","volume":"51","author":"Nasser A","year":"2021","unstructured":"Nasser A, Liranso T, Adewole T, et al.. A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD. Psychopharmacol Bull. 2021, 51:43-64.","journal-title":"Psychopharmacol Bull"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2015.08.016","article-title":"A randomized, placebo-controlled trial of guanfacine extended release in adolescents with attention-deficit\/hyperactivity disorder","volume":"54","author":"Wilens TE","year":"2015","unstructured":"Wilens TE, Robertson B, Sikirica V, et al.. A randomized, placebo-controlled trial of guanfacine extended release in adolescents with attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2015, 54:916-25.e2. 10.1016\/j.jaac.2015.08.016","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2013.11.005","article-title":"Efficacy and safety of atomoxetine in children and adolescents with attention-deficit\/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression","volume":"53","author":"Schwartz S","year":"2014","unstructured":"Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit\/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry. 2014, 53:174-87. 10.1016\/j.jaac.2013.11.005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2015.03.006","article-title":"Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion","volume":"178","author":"Stuhec M","year":"2015","unstructured":"Stuhec M, Munda B, Svab V, Locatelli I. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion. J Affect Disord. 2015, 178:149-59. 10.1016\/j.jad.2015.03.006","journal-title":"J Affect Disord"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40279-023-01927-9","article-title":"The perils of misinterpreting and misusing \"publication bias\" in meta-analyses: an education review on funnel plot-based methods","volume":"54","author":"Afonso J","year":"2024","unstructured":"Afonso J, Ramirez-Campillo R, Clemente FM, B\u00fcttner FC, Andrade R. The perils of misinterpreting and misusing \"publication bias\" in meta-analyses: an education review on funnel plot-based methods. Sports Med. 2024, 54:257-69. 10.1007\/s40279-023-01927-9","journal-title":"Sports Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/461848-efficacy-and-tolerability-of-viloxazine-extended-release-for-attention-deficithyperactivity-disorder-in-adolescents-and-adults-a-systematic-review-with-qualitative-synthesis-of-all-studies-and-meta-analysis-of-adolescent-data","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:45:29Z","timestamp":1773420329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/461848-efficacy-and-tolerability-of-viloxazine-extended-release-for-attention-deficithyperactivity-disorder-in-adolescents-and-adults-a-systematic-review-with-qualitative-synthesis-of-all-studies-and-meta-analysis-of-adolescent-data"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.105176","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,13]]}}}